[Pubmed] Biomarker-Guided Diagnosis of Riboflavin Transporter Deficiency Presenting as Seronegative Myasthenia Gravis: A

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6500
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Chrome

[Pubmed] Biomarker-Guided Diagnosis of Riboflavin Transporter Deficiency Presenting as Seronegative Myasthenia Gravis: A

Message par RSS-Bot »


Genet Test Mol Biomarkers. 2026 Sep 26:19450265261493084. doi: 10.1177/19450265261493084. Online ahead of print.

ABSTRACT

BACKGROUND: Brown-Vialetto-Van Laere syndrome (BVVLS) is a rare, treatable neurodegenerative disorder caused by riboflavin transporter gene variants (SLC52A2, SLC52A3). Early symptoms can mimic neuromuscular junction disorders, causing diagnostic delays.

CASE PRESENTATION: A 3.5-year-old girl from consanguineous parents presented at 2.5 years with isolated bilateral ptosis, later developing dysphagia, dysphonia, facial diplegia, stridor, and respiratory compromise. Examination revealed tongue atrophy with fasciculations and bulbar weakness but normal limb strength. Diagnosed with seronegative myasthenia gravis, she failed to respond to corticosteroids, pyridostigmine, salbutamol, and intravenous immunoglobulin. Absence of fatigability, lower motor neuron signs, and a sibling history of hearing loss and bulbar palsy prompted genetic testing revealed a homozygous missense variant in SLC52A3 (c.670T > C; p.Phe224Leu). High-dose riboflavin (up to 50 mg/kg/day) led to gradual improvement in bulbar function, resolution of stridor, and respiratory stabilization, though ptosis and tongue fasciculations persisted.

CONCLUSION: This report is novel in using clinical response to riboflavin as a functional biomarker for riboflavin transporter deficiency (RTD) in a patient with a variant of uncertain significance, unlike prior cases with definitive genetics. Empiric riboflavin challenge offers a practical framework when genetic results are ambiguous. RTD should be suspected in children with treatment-resistant, non-fluctuating ptosis and bulbar weakness, particularly with consanguinity or family history of hearing loss and bulbar palsy. Early high-dose riboflavin prevents decline, while immunosuppression is ineffective and potentially harmful.

PMID:42799589 | DOI:10.1177/19450265261493084


Source: https://pubmed.ncbi.nlm.nih.gov/4279958 ... 5&v=2.20.1
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »